ImmunityBio (IBRX) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmunityBio (IBRX) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 290.0% versus a loss of 4.3%. Over five years, IBRX leads with a +4.8% price change compared with -16.0% for QGEN. ImmunityBio is the larger company by market cap ($10.50 billion vs $9.20 billion), about 1.1 times the size.
Qiagen N.V. pays a dividend yielding 0.82%, while ImmunityBio does not currently pay one. Qiagen N.V. converts more of its revenue into profit, with a net margin of 20.3% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | QGEN |
|---|---|---|
| Share price | $9.91 | $44.53 |
| Market cap | $10.50B | $9.20B |
| 1-day change | +1.64% | -0.58% |
| YTD return | +392.42% | -0.40% |
| 1-year return | +290.00% | -4.29% |
| 5-year return | +4.84% | -15.95% |
| P/E ratio (TTM) | — | 22.60 |
| Forward P/E | — | 17.04 |
| EPS (TTM) | $-0.96 | $1.97 |
| Dividend yield | 0.00% | 0.82% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | $113.29M | $2.09B |
| Revenue growth (YoY) | +668.31% | +5.65% |
| Net income (latest FY) | $-351.40M | $424.88M |
| Gross margin | 99.34% | 62.18% |
| Operating margin | -226.00% | 22.29% |
| Net margin | -310.18% | 20.33% |
| 52-week high | $12.43 | $57.82 |
| 52-week low | $1.95 | $32.53 |
| Distance from 52-week high | -20.27% | -22.99% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +28.66% | +6.15% |
| Average volume | 10.29M | 2.75M |
| Shares outstanding | 1.06B | 206.50M |
| Employees | 684 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed QGEN by 294.3 percentage points over the past year.
- Qiagen N.V. is more profitable, keeping 20.3 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +5.65%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
IBRX vs QGEN FAQ
Which is bigger, ImmunityBio or Qiagen N.V.?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.50B compared with $9.20B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, IBRX or QGEN?
IBRX returned +290.00% over the past 12 months, compared with -4.29% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, ImmunityBio or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.82%, while ImmunityBio does not currently pay a regular dividend.
Are ImmunityBio and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.